{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:13:04Z","timestamp":1792782784518,"version":"4.5.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T00:00:00Z","timestamp":1595808000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T00:00:00Z","timestamp":1595808000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Sirtex Medical United Kingdom Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Limited treatment options are available in chemotherapy-refractory metastatic colorectal cancer (mCRC). The objective was to conduct a systematic literature review (SLR) and exploratory network meta-analysis (NMA) to compare the tolerability and effectiveness of SIRT with Y-90 resin microspheres, regorafenib, TAS-102 (trifluridine\/tipiracil), and best supportive care (BSC) as third-line treatment in patients with mCRC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An SLR was conducted to identify studies comparing two or more of the treatments and reporting overall survival (OS), progression-free survival, tumor response, or adverse event (AE) incidence. An exploratory NMA was conducted to compare hazard ratios (HRs) for OS using Markov chain Monte Carlo (MCMC) techniques.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seven studies were identified in the SLR: two double-blind randomized-controlled trials (RCT) for each drug, one open-label RCT, and two non-randomized comparative studies for SIRT. Patient selection criteria differed between studies, with SIRT studies including patients with liver-dominant colorectal metastases. Nausea and vomiting were more frequent with TAS-102 than regorafenib or SIRT; diarrhea was more common with TAS-102 and regorafenib than SIRT. The exploratory NMA suggested that all active treatments improved OS, with HRs of 0.48 (95% CrI 0.30\u20130.78) for SIRT with Y-90 resin microspheres, 0.63 (0.38\u20131.03) for TAS-102, and 0.67 (0.40\u20131.08) for regorafenib each compared to BSC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Regorafenib, TAS-102 and SIRT using Y-90 resin microspheres are more effective than BSC in third-line treatment of\u00a0mCRC; however, study heterogeneity made comparisons between active treatments challenging. SIRT is a viable treatment for third-line mCRC and its favorable AE profile should be considered in the therapeutic decision-making process.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00432-020-03315-6","type":"journal-article","created":{"date-parts":[[2020,7,26]],"date-time":"2020-07-26T22:02:26Z","timestamp":1595800946000},"page":"2575-2587","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Systematic review and network meta-analyses of third-line treatments for metastatic colorectal cancer"],"prefix":"10.1007","volume":"146","author":[{"given":"Thomas","family":"Walter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil S.","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9873-7507","authenticated-orcid":false,"given":"Richard F.","family":"Pollock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Colaone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suki","family":"Shergill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,27]]},"reference":[{"issue":"2","key":"3315_CR1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.clcc.2017.10.016","volume":"17","author":"ABK Abrahao","year":"2018","unstructured":"Abrahao ABK, Ko Y-J, Berry S, Chan KKW (2018) A comparison of regorafenib and TAS-102 for metastatic colorectal cancer: a systematic review and network meta-analysis. Clin Colorectal Cancer 17(2):113\u2013120","journal-title":"Clin Colorectal Cancer"},{"issue":"2","key":"3315_CR2","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/jnci\/djt371","volume":"106","author":"TA Abrams","year":"2014","unstructured":"Abrams TA, Meyer G, Schrag D et al (2014) Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer. J Natl Cancer Inst 106(2):371","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"3315_CR3","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1634\/theoncologist.2012-0121","volume":"17","author":"R Adam","year":"2012","unstructured":"Adam R, De Gramont A, Figueras J et al (2012) The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist 17(10):1225\u20131239","journal-title":"Oncologist"},{"issue":"8","key":"3315_CR4","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1080\/0284186X.2019.1605192","volume":"58","author":"SE Andersen","year":"2019","unstructured":"Andersen SE, Andersen IB, Jensen BV, Pfeiffer P, Ota T, Larsen JS (2019) A systematic review of observational studies of trifluridine\/tipiracil (TAS-102) for metastatic colorectal cancer. Acta Oncol 58(8):1149\u20131157","journal-title":"Acta Oncol"},{"issue":"2","key":"3315_CR5","doi-asserted-by":"crossref","first-page":"e000495","DOI":"10.1136\/esmoopen-2019-000495","volume":"4","author":"G Argiles","year":"2019","unstructured":"Argiles G, Arnold D, Prager G, Sobrero AF, Van Cutsem E (2019) Maximising clinical benefit with adequate patient management beyond the second line in mCRC. ESMO Open 4(2):e000495","journal-title":"ESMO Open"},{"key":"3315_CR6","unstructured":"Bayer AG (2018) STIVARGA\u00ae summary of product characteristics. European Medicines Agency, Amsterdam. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/stivarga-epar-product-information_en.pdf. Accessed 28 Oct 2019"},{"issue":"8","key":"3315_CR7","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/S1470-2045(19)30272-4","volume":"20","author":"TS Bekaii-Saab","year":"2019","unstructured":"Bekaii-Saab TS, Ou F-S, Ahn DH, Boland PM, Ciombor KK, Heying EN et al (2019) Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. Lancet Oncol 20(8):1070\u20131082","journal-title":"Lancet Oncol"},{"key":"3315_CR8","unstructured":"Benson AB, Venook AP, Al-Hawary MM, Mustafa A, Chen YJ, Ciombor KK et al (2020) NCCN clinical practice guidelines in oncology: colon cancer, version 3. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/colon.pdf. Accessed 3 June 2020"},{"issue":"1","key":"3315_CR9","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jvir.2011.09.028","volume":"23","author":"L Bester","year":"2012","unstructured":"Bester L, Meteling B, Pocock N, Pavlakis N, Chua TC, Saxena A et al (2012) Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients. J Vasc Interv Radiol 23(1):96\u2013105","journal-title":"J Vasc Interv Radiol"},{"issue":"6","key":"3315_CR10","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394\u2013424","journal-title":"CA Cancer J Clin"},{"key":"3315_CR11","unstructured":"Brooks SP, Gelman A (1998) General methods for monitoring convergence of iterative simulations. J Comput Graph Stat. https:\/\/www.tandfonline.com\/doi\/abs\/10.1080\/10618600.1998.10474787. Accessed 17 June 2019"},{"key":"3315_CR12","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s13643-015-0133-0","volume":"4","author":"C Cameron","year":"2015","unstructured":"Cameron C, Fireman B, Hutton B, Clifford T, Coyle D, Wells G, Dormuth CR, Platt R, Toh S (2015) Network meta-analysis incorporating randomized controlled trials and non-randomized comparative cohort studies for assessing the safety and effectiveness of medical treatments: challenges and opportunities. Syst Rev 4:147","journal-title":"Syst Rev"},{"issue":"3","key":"3315_CR13","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/sj.bjc.6605770","volume":"103","author":"M Cosimelli","year":"2010","unstructured":"Cosimelli M, Golfieri R, Cagol PP, Carpanese L, Sciuto R, Maini CL et al (2010) Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer 103(3):324\u2013331","journal-title":"Br J Cancer"},{"issue":"s5","key":"3315_CR14","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1093\/annonc\/mdy149.011","volume":"29","author":"M Ducreux","year":"2018","unstructured":"Ducreux M, Petersen L, \u00d6hler L, Bergamo F, Metges J, de Groot J et al (2018) O-012: safety and effectiveness of regorafenib in patients with metastatic colorectal cancer (mCRC) in routine clinical practice: final analysis from the prospective, observational CORRELATE study. Ann Oncol 29(s5):104","journal-title":"Ann Oncol"},{"key":"3315_CR15","doi-asserted-by":"crossref","first-page":"175883591985649","DOI":"10.1177\/1758835919856494","volume":"11","author":"M Ducreux","year":"2019","unstructured":"Ducreux M, Chamseddine A, Laurent-Puig P, Smolenschi C, Hollebecque A, Dartigues P, Samallin E, Boige V, Malka D, Gelli M (2019) Molecular targeted therapy of BRAF-mutant colorectal cancer. Ther Adv Med Oncol 11:1758835919856494","journal-title":"Ther Adv Med Oncol"},{"issue":"8","key":"3315_CR16","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1002\/sim.7223","volume":"36","author":"O Efthimiou","year":"2017","unstructured":"Efthimiou O, Mavridis D, Debray TP, Samara M, Belger M, Siontis GC, Leucht S, Salanti G (2017) GetReal work package 4. Combining randomized and non-randomized evidence in network meta-analysis. Stat Med 36(8):1210\u20131226","journal-title":"Stat Med"},{"issue":"8","key":"3315_CR17","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.2967\/jnumed.112.116426","volume":"54","author":"WP Fendler","year":"2013","unstructured":"Fendler WP, Tiega DBP, Ilhan H, Paprottka PM, Heinemann V, Jakobs TF et al (2013) Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer. J Nucl Med 54(8):1202\u20131208","journal-title":"J Nucl Med"},{"key":"3315_CR18","unstructured":"Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Pi\u00f1eros M, Znaor A, Soerjomataram I, Bray F (2019) Global cancer observatory: cancer tomorrow. International Agency for Research on Cancer, Lyon. https:\/\/gco.iarc.fr\/tomorrow. Accessed 18 Oct 2019"},{"issue":"2","key":"3315_CR19","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.dld.2013.07.002","volume":"46","author":"F Foubert","year":"2014","unstructured":"Foubert F, Matysiak-Budnik T, Touchefeu Y (2014) Options for metastatic colorectal cancer beyond the second line of treatment. Dig Liver Dis 46(2):105\u2013112","journal-title":"Dig Liver Dis"},{"issue":"8","key":"3315_CR20","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s11547-015-0504-6","volume":"120","author":"R Golfieri","year":"2015","unstructured":"Golfieri R, Mosconi C, Giampalma E, Cappelli A, Galaverni MC, Pettinato C et al (2015) Selective transarterial radioembolisation of unresectable liver-dominant colorectal cancer refractory to chemotherapy. Radiol Med (Torino) 120(8):767\u2013776","journal-title":"Radiol Med (Torino)"},{"issue":"9863","key":"3315_CR21","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey A, Cutsem EV, Sobrero A, Siena S, Falcone A, Ychou M et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381(9863):303\u2013312","journal-title":"Lancet"},{"issue":"3","key":"3315_CR22","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/jrsm.1187","volume":"7","author":"N Hawkins","year":"2016","unstructured":"Hawkins N, Scott DA, Woods B (2016) \u2018Arm-based\u2019 parameterization for network meta-analysis. Res Synth Methods 7(3):306\u2013313","journal-title":"Res Synth Methods"},{"issue":"23","key":"3315_CR23","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1200\/JCO.2010.28.5643","volume":"28","author":"A Hendlisz","year":"2010","unstructured":"Hendlisz A, den Eynde MV, Peeters M, Maleux G, Lambert B, Vannoote J et al (2010) Phase III trial comparing protracted intravenous fluorouracil infusion alone or with Yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol 28(23):3687\u20133694","journal-title":"J Clin Oncol"},{"issue":"2","key":"3315_CR24","doi-asserted-by":"crossref","first-page":"443","DOI":"10.21037\/jgo.2020.01.09","volume":"11","author":"DR Jeyarajah","year":"2020","unstructured":"Jeyarajah DR, Doyle MBM, Espat NJ, Hansen PD, Iannitti DA, Kim J, Thambi-Pillai T, Visser BC (2020) Role of yttrium-90 selective internal radiation therapy in the treatment of liver-dominant metastatic colorectal cancer: an evidence-based expert consensus algorithm. J Gastrointest Oncol 11(2):443\u2013460","journal-title":"J Gastrointest Oncol"},{"key":"3315_CR25","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s11888-019-00437-z","volume":"15","author":"S Kamatham","year":"2019","unstructured":"Kamatham S, Shahjehan F, Kasi PM (2019) Immune checkpoint inhibitors in metastatic colorectal cancer: current status, recent advances, and future directions. Curr Colorectal Cancer Rep 15:112\u2013121","journal-title":"Curr Colorectal Cancer Rep"},{"issue":"7","key":"3315_CR26","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1634\/theoncologist.2013-0442","volume":"19","author":"H Kennecke","year":"2014","unstructured":"Kennecke H, Yu J, Gill S et al (2014) Effect of M1a and M1b category in metastatic colorectal cancer. Oncologist 19(7):720\u2013726","journal-title":"Oncologist"},{"issue":"2","key":"3315_CR27","first-page":"134","volume":"6","author":"AS Kennedy","year":"2015","unstructured":"Kennedy AS, Ball D, Cohen SJ, Cohn M, Coldwell DM, Drooz A et al (2015) Multicenter evaluation of the safety and efficacy of radioembolization in patients with unresectable colorectal liver metastases selected as candidates for 90Y resin microspheres. J Gastrointest Oncol 6(2):134\u2013142","journal-title":"J Gastrointest Oncol"},{"issue":"17","key":"3315_CR28","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","volume":"381","author":"S Kopetz","year":"2019","unstructured":"Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, Wasan H, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Pfeiffer P, Orlov S, Lonardi S, Elez E, Kim TW, Schellens JHM, Guo C, Krishnan A, Dekervel J, Morris V, Calvo Ferrandiz A, Tarpgaard LS, Braun M, Gollerkeri A, Keir C, Maharry K, Pickard M, Christy-Bittel J, Anderson L, Sandor V, Tabernero J (2019) Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Engl J Med 381(17):1632\u20131643","journal-title":"N Engl J Med"},{"issue":"4","key":"3315_CR29","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/cncr.27802","volume":"119","author":"R Kumar","year":"2013","unstructured":"Kumar R, Jain K, Beeke C et al (2013) A population-based study of metastatic colorectal cancer in individuals aged\u2009\u2265\u200980\u00a0years: findings from the South Australian Clinical Registry for Metastatic Colorectal Cancer. Cancer 119(4):722\u2013728","journal-title":"Cancer"},{"issue":"2","key":"3315_CR30","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.clcc.2013.11.008","volume":"13","author":"R Kumar","year":"2014","unstructured":"Kumar R, Price TJ, Beeke C et al (2014) Colorectal cancer survival: an analysis of patients with metastatic disease synchronous and metachronous with the primary tumor. Clin Colorectal Cancer 13(2):87\u201393","journal-title":"Clin Colorectal Cancer"},{"issue":"8","key":"3315_CR31","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.jvir.2015.05.032","volume":"26","author":"SJ Lahti","year":"2015","unstructured":"Lahti SJ, Xing M, Zhang D, Lee JJ, Magnetta MJ, Kim HS (2015) KRAS status as an independent prognostic factor for survival after Yttrium-90 radioembolization therapy for unresectable colorectal cancer liver metastases. J Vasc Interv Radiol 26(8):1102\u20131111","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"3315_CR32","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.19.02107","volume":"38","author":"DT Le","year":"2020","unstructured":"Le DT, Kim TW, Van Cutsem E, Geva R, J\u00e4ger D, Hara H, Burge M, O\u2019Neil B, Kavan P, Yoshino T, Guimbaud R, Taniguchi H, Elez E, Al-Batran SE, Boland PM, Crocenzi T, Atreya CE, Cui Y, Dai T, Marinello P, Diaz LA Jr, Andr\u00e9 T (2020) Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J Clin Oncol 38(1):11\u201319","journal-title":"J Clin Oncol"},{"key":"3315_CR33","unstructured":"Les Laboratoires Servier (2016) LONSURF\u00ae summary of product characteristics. European Medicines Agency, Amsterdam. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lonsurf-epar-product-information_en.pdf. Accessed 28 Oct 2019"},{"issue":"6","key":"3315_CR34","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","volume":"16","author":"J Li","year":"2015","unstructured":"Li J, Qin S, Xu R, Yau TCC, Ma B, Pan H et al (2015) Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 16(6):619\u2013629","journal-title":"Lancet Oncol"},{"issue":"4","key":"3315_CR35","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3109\/0284186X.2015.1101151","volume":"55","author":"G Maleux","year":"2016","unstructured":"Maleux G, Deroose C, Laenen A, Verslype C, Heye S, Haustermans K et al (2016) Yttrium-90 radioembolization for the treatment of chemorefractory colorectal liver metastases: technical results, clinical outcome and factors potentially influencing survival. Acta Oncol Stockh Swed 55(4):486\u2013495","journal-title":"Acta Oncol Stockh Swed"},{"key":"3315_CR36","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ctrv.2018.12.006","volume":"73","author":"G Mauri","year":"2019","unstructured":"Mauri G, Pizzutilo EG, Amatu A, Bencardino K, Palmeri L, Bonazzina EF, Tosi F, Carlo Stella G, Burrafato G, Scaglione F, Marsoni S, Siravegna G, Bardelli A, Siena S, Sartore-Bianchi A (2019) Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: systematic review of different strategies. Cancer Treat Rev 73:41\u201353","journal-title":"Cancer Treat Rev"},{"issue":"20","key":"3315_CR37","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N et al (2015) Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372(20):1909\u20131919","journal-title":"N Engl J Med"},{"issue":"2","key":"3315_CR38","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/sj.bjc.6605737","volume":"103","author":"LJM Mekenkamp","year":"2010","unstructured":"Mekenkamp LJM, Koopman M, Teerenstra S et al (2010) Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases. Br J Cancer 103(2):159\u2013164","journal-title":"Br J Cancer"},{"key":"3315_CR39","first-page":"e571261","volume":"2011","author":"GW Nace","year":"2011","unstructured":"Nace GW, Steel JL, Amesur N, Zajko A, Nastasi BE, Joyce J et al (2011) Yttrium-90 radioembolization for colorectal cancer liver metastases: a single institution experience. Int J Surg Oncol 2011:e571261","journal-title":"Int J Surg Oncol"},{"issue":"5","key":"3315_CR40","doi-asserted-by":"crossref","first-page":"253","DOI":"10.4174\/astr.2015.88.5.253","volume":"88","author":"SY Oh","year":"2015","unstructured":"Oh SY, Kim DY, Suh KW (2015) Oncologic outcomes following metastasectomy in colorectal cancer patients developing distant metastases after initial treatment. Ann Surg Treat Res 88(5):253\u2013259","journal-title":"Ann Surg Treat Res"},{"issue":"8","key":"3315_CR41","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","volume":"36","author":"MJ Overman","year":"2018","unstructured":"Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A, Sawyer MB, Hendlisz A, Neyns B, Svrcek M, Moss RA, Ledeine JM, Cao ZA, Kamble S, Kopetz S, Andr\u00e9 T (2018) Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol 36(8):773\u2013779","journal-title":"J Clin Oncol"},{"issue":"10","key":"3315_CR42","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.dld.2019.05.035","volume":"51","author":"JM Phelip","year":"2019","unstructured":"Phelip JM, Tougeron D, L\u00e9onard D, Benhaim L, Desolneux G, Dupr\u00e9 A et al (2019) Metastatic colorectal cancer (mCRC): french intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). Dig Liver Dis 51(10):1357\u20131363","journal-title":"Dig Liver Dis"},{"key":"3315_CR43","unstructured":"Plummer M (2003) JAGS: a program for analysis of Bayesian graphical models using Gibbs sampling. In: Proceedings of the 3rd International Workshop on Distributed Statistical Computing (DSC 2003), March 20-22, Vienna, Austria. ISSN 1609-395X"},{"issue":"4","key":"3315_CR44","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1093\/jjco\/hyt002","volume":"43","author":"S Sadahiro","year":"2013","unstructured":"Sadahiro S, Suzuki T, Tanaka A et al (2013) Hematogenous metastatic patterns of curatively resected colon cancer were different from those of stage IV and autopsy cases. Jpn J Clin Oncol 43(4):444\u2013447","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"3315_CR45","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1002\/hep.29207","volume":"66","author":"B Sangro","year":"2017","unstructured":"Sangro B, Mart\u00ednez-Urbistondo D, Bester L, Bilbao JI, Coldwell DM, Flamen P et al (2017) Prevention and treatment of complications of selective internal radiation therapy: expert guidance and systematic review. Hepatol Baltim Md. 66(3):969\u2013982","journal-title":"Hepatol Baltim Md."},{"issue":"3","key":"3315_CR46","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1245\/s10434-014-4164-x","volume":"22","author":"A Saxena","year":"2015","unstructured":"Saxena A, Meteling B, Kapoor J, Golani S, Morris DL, Bester L (2015) Is yttrium-90 radioembolization a viable treatment option for unresectable, chemorefractory colorectal cancer liver metastases? A large single-center experience of 302 patients. Ann Surg Oncol 22(3):794\u2013802","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"3315_CR47","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1007\/s00270-011-0234-7","volume":"35","author":"R Seidensticker","year":"2012","unstructured":"Seidensticker R, Denecke T, Kraus P, Seidensticker M, Mohnike K, Fahlke J et al (2012) Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases. Cardiovasc Interv Radiol 35(5):1066\u20131073","journal-title":"Cardiovasc Interv Radiol"},{"issue":"4","key":"3315_CR48","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.clcc.2015.06.003","volume":"14","author":"CT Sofocleous","year":"2015","unstructured":"Sofocleous CT, Violari EG, Sotirchos VS, Shady W, Gonen M, Pandit-Taskar N et al (2015) Radioembolization as a salvage therapy for heavily pretreated patients with colorectal cancer liver metastases: factors that affect outcomes. Clin Colorectal Cancer 14(4):296\u2013305","journal-title":"Clin Colorectal Cancer"},{"issue":"9","key":"3315_CR49","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1634\/theoncologist.2019-0189","volume":"24","author":"MB Sonbol","year":"2019","unstructured":"Sonbol MB, Benkhadra R, Wang Z, Firwana B, Walden DJ, Mody K et al (2019) A systematic review and network meta-analysis of regorafenib and TAS-102 in refractory metastatic colorectal cancer. Oncologist 24(9):1174\u20131179","journal-title":"Oncologist"},{"issue":"12","key":"3315_CR50","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1111\/hpb.12307","volume":"16","author":"S Tohme","year":"2014","unstructured":"Tohme S, Sukato D, Nace GW, Zajko A, Amesur N, Orons P et al (2014) Survival and tolerability of liver radioembolization: a comparison of elderly and younger patients with metastatic colorectal cancer. HPB 16(12):1110\u20131116","journal-title":"HPB"},{"issue":"3","key":"3315_CR51","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/ije\/dys041","volume":"41","author":"RM Turner","year":"2012","unstructured":"Turner RM, Davey J, Clarke MJ, Thompson SG, Higgins JPT (2012) Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. Int J Epidemiol 41(3):818\u2013827","journal-title":"Int J Epidemiol"},{"key":"3315_CR52","unstructured":"US Food and Drug Administration (2020) FDA approves encorafenib in combination with cetuximab for metastatic colorectal cancer with a BRAF V600E mutation. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-encorafenib-combination-cetuximab-metastatic-colorectal-cancer-braf-v600e-mutation. Accessed 3 June 2020"},{"key":"3315_CR53","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1200\/JCO.2014.59.4812","volume":"33","author":"E Van Cutsem","year":"2015","unstructured":"Van Cutsem E, Lenz HJ, K\u00f6hne CH, Heinemann V, Tejpar S, Melez\u00ednek I, Beier F, Stroh C, Rougier P, van Krieken JH, Ciardiello F (2015) Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol 33:692\u2013700","journal-title":"J Clin Oncol"},{"issue":"8","key":"3315_CR54","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","volume":"27","author":"E Van Cutsem","year":"2016","unstructured":"Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27(8):1386\u20131422","journal-title":"Ann Oncol"},{"issue":"5","key":"3315_CR55","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10585-015-9719-0","volume":"32","author":"LG van der Geest","year":"2015","unstructured":"van der Geest LG, Lam-Boer J, Koopman M et al (2015) Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases. Clin Exp Metastasis 32(5):457\u2013465","journal-title":"Clin Exp Metastasis"},{"issue":"1","key":"3315_CR56","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1463-1318.2010.02539.x","volume":"14","author":"AE van der Pool","year":"2012","unstructured":"van der Pool AE, Damhuis RA, Ijzermans JN et al (2012) Trends in incidence, treatment and survival of patients with stage IV colorectal cancer: a population-based series. Colorectal Dis 14(1):56\u201361","journal-title":"Colorectal Dis"},{"key":"3315_CR57","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-019-02182-z","author":"R Vera","year":"2019","unstructured":"Vera R, Gonz\u00e1lez-Flores E, Rubio C, Urbano J, Valero Camps M, Ciampi-Dopazo JJ, Orcajo Rinc\u00f3n J, Morillo Mac\u00edas V, Gomez Braco MA, Suarez-Artacho G (2019) Multidisciplinary management of liver metastases in patients with colorectal cancer: a consensus of SEOM, AEC, SEOR, SERVEI, and SEMNIM. Clin Transl Oncol. https:\/\/doi.org\/10.1007\/s12094-019-02182-z","journal-title":"Clin Transl Oncol"},{"issue":"10","key":"3315_CR58","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S1470-2045(12)70345-5","volume":"13","author":"T Yoshino","year":"2012","unstructured":"Yoshino T, Mizunuma N, Yamazaki K, Nishina T, Komatsu Y, Baba H et al (2012) TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 13(10):993\u20131001","journal-title":"Lancet Oncol"},{"issue":"5","key":"3315_CR59","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1200\/JOP.091010","volume":"5","author":"SY Zafar","year":"2009","unstructured":"Zafar SY, Marcello JE, Wheeler JL et al (2009) Longitudinal patterns of chemotherapy use in metastatic colorectal cancer. J Oncol Pract 5(5):228\u2013233","journal-title":"J Oncol Pract"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-020-03315-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-020-03315-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-020-03315-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T19:29:11Z","timestamp":1627327751000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-020-03315-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,27]]},"references-count":59,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["3315"],"URL":"https:\/\/doi.org\/10.1007\/s00432-020-03315-6","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,27]]},"assertion":[{"value":"24 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"TW has no conflicts of interest to declare; NH is a partner of Visible Analytics Ltd, which received consultancy fees, research grant, and expenses from Sirtex Medical United Kingdom Ltd (a subsidiary of Sirtex Medical Ltd. the manufacturer of SIR-Spheres Y-90 resin microspheres) to conduct the systematic literature review and network meta-analysis; RFP is a director and shareholder of Covalence Research Ltd, which received consultancy fees from Sirtex Medical United Kingdom Ltd, to conduct sensitivity analyses, generate tables and figures, and write the manuscript; FC is a full-time employee of Sirtex Medical United Kingdom Ltd; SS is a director and full-time employee of Sirtex Medical United Kingdom Ltd; PR reports honoraria from Amgen, Servier, Shire, Sirtex, BMS, Pierre Fabre, and Roche, participation in advisory board meetings for Shire, Celgene, BMS, Pierre Fabre, receipt of travel support from Amgen, BMS, Bayer, Roche, and Servier, and his institution has received research funding from Sanofi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}